X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES VENUS REMEDIES ALKEM LABORATORIES/
VENUS REMEDIES
 
P/E (TTM) x - -1.5 - View Chart
P/BV x 6.1 0.1 5,591.7% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALKEM LABORATORIES   VENUS REMEDIES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
VENUS REMEDIES
Mar-18
ALKEM LABORATORIES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,589126 1,262.1%   
Low Rs1,23261 2,016.4%   
Sales per share (Unadj.) Rs417.5301.8 138.3%  
Earnings per share (Unadj.) Rs56.3-24.9 -226.4%  
Cash flow per share (Unadj.) Rs64.72.5 2,542.9%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.9293.3 99.9%  
Shares outstanding (eoy) m119.5712.34 969.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,090.6%   
Avg P/E ratio x25.1-3.8 -666.5%  
P/CF ratio (eoy) x21.836.7 59.3%  
Price / Book Value ratio x4.80.3 1,510.3%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6531,154 14,617.3%   
No. of employees `000NA0.9 0.0%   
Total wages/salary Rs m9,171393 2,333.1%   
Avg. sales/employee Rs ThNM4,026.1-  
Avg. wages/employee Rs ThNM425.0-  
Avg. net profit/employee Rs ThNM-331.8-  
INCOME DATA
Net Sales Rs m49,9153,724 1,340.3%  
Other income Rs m1,64523 7,311.6%   
Total revenues Rs m51,5613,747 1,376.2%   
Gross profit Rs m8,482395 2,148.5%  
Depreciation Rs m1,006338 297.3%   
Interest Rs m671354 189.3%   
Profit before tax Rs m8,451-275 -3,069.7%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60632 5,082.3%   
Profit after tax Rs m6,731-307 -2,193.3%  
Gross profit margin %17.010.6 160.3%  
Effective tax rate %19.0-11.5 -165.6%   
Net profit margin %13.5-8.2 -163.6%  
BALANCE SHEET DATA
Current assets Rs m27,0622,638 1,026.0%   
Current liabilities Rs m15,3242,305 664.9%   
Net working cap to sales %23.58.9 263.0%  
Current ratio x1.81.1 154.3%  
Inventory Days Days67135 49.1%  
Debtors Days Days4146 89.1%  
Net fixed assets Rs m12,6104,871 258.9%   
Share capital Rs m239123 193.8%   
"Free" reserves Rs m34,4903,496 986.6%   
Net worth Rs m35,0273,619 967.8%   
Long term debt Rs m1,2121,374 88.2%   
Total assets Rs m54,3877,509 724.3%  
Interest coverage x13.60.2 6,100.3%   
Debt to equity ratio x00.4 9.1%  
Sales to assets ratio x0.90.5 185.0%   
Return on assets %13.60.6 2,155.9%  
Return on equity %19.2-8.5 -226.6%  
Return on capital %24.91.6 1,571.2%  
Exports to sales %12.90-   
Imports to sales %3.113.9 22.2%   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540517 298.2%   
Fx inflow Rs m6,5630-   
Fx outflow Rs m3,012517 583.1%   
Net fx Rs m3,552-517 -687.6%   
CASH FLOW
From Operations Rs m7,259514 1,411.1%  
From Investments Rs m1,864-123 -1,514.4%  
From Financial Activity Rs m-9,273-387 2,395.4%  
Net Cashflow Rs m-1504 -3,571.4%  

Share Holding

Indian Promoters % 66.9 32.9 203.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.2 18,388.9%  
FIIs % 0.0 0.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 66.4 -  
Shareholders   68,381 20,121 339.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and Energy Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

The Jet Airways Crisis in 6 Charts(Sector Info)

Mar 5, 2019

What happened to Jet Airways, once among top 3 airlines in India? Is it another Kingfisher in the making? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 18, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - AUROBINDO PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS